Contract research firm GVK Bio on Thursday signed a definitive agreement to acquire Vanta Bioscience for an undisclosed sum.
The US-headquartered Vanta Bioscience offers toxicology evaluation services for pharmaceutical, biotech, food supplements and feed additives industries.
"The acquisition is in line with our business strategy of being an integrated drug discovery services provider for our customers. We are constantly investing in upgrading our capabilities to provide world-class R&D services. Vanta Bioscience further advances our position as we expand our service offering in GLP (good laboratory practice) toxicology," said GVK Bio CEO Manni Kantipudi.
Vanta Bioscience vice president and general manager Gerard Schwickerath said, "Vanta Bioscience team is pleased that the world-class research GLP and AAALAC accredited organisation will continue under the direction of GVK Bio. We are delighted to transition into an organisation that can expand our offerings and provide further opportunities to our clients and staff."